2axa: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[Image:2axa.gif|left|200px]] | [[Image:2axa.gif|left|200px]] | ||
<!-- | |||
The line below this paragraph, containing "STRUCTURE_2axa", creates the "Structure Box" on the page. | |||
You may change the PDB parameter (which sets the PDB file loaded into the applet) | |||
or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |||
or leave the SCENE parameter empty for the default display. | |||
--> | |||
{{STRUCTURE_2axa| PDB=2axa | SCENE= }} | |||
}} | |||
'''Crystal Structure Of The Androgen Receptor Ligand Binding Domain In Complex With S-1''' | '''Crystal Structure Of The Androgen Receptor Ligand Binding Domain In Complex With S-1''' | ||
| Line 30: | Line 27: | ||
[[Category: Dalton, J T.]] | [[Category: Dalton, J T.]] | ||
[[Category: Miller, D D.]] | [[Category: Miller, D D.]] | ||
[[Category: | [[Category: Transcription]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 19:35:10 2008'' | |||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | |||
Revision as of 19:35, 3 May 2008
Crystal Structure Of The Androgen Receptor Ligand Binding Domain In Complex With S-1
OverviewOverview
The mechanism by which the androgen receptor (AR) distinguishes between agonist and antagonist ligands is poorly understood. AR antagonists are currently used to treat prostate cancer. However, mutations commonly develop in patients that convert these compounds to agonists. Recently, our laboratory discovered selective androgen receptor modulators, which structurally resemble the nonsteroidal AR antagonists bicalutamide and hydroxyflutamide but act as agonists for the androgen receptor in a tissue-selective manner. To investigate why subtle structural changes to both the ligand and the receptor (i.e. mutations) result in drastic changes in activity, we studied structure-activity relationships for nonsteroidal AR ligands through crystallography and site-directed mutagenesis, comparing bound conformations of R-bicalutamide, hydroxyflutamide, and two previously reported nonsteroidal androgens, S-1 and R-3. These studies provide the first crystallographic evidence of the mechanism by which nonsteroidal ligands interact with the wild type AR. We have shown that changes induced to the positions of Trp-741, Thr-877, and Met-895 allow for ligand accommodation within the AR binding pocket and that a water-mediated hydrogen bond to the backbone oxygen of Leu-873 and the ketone of hydroxyflutamide is present when bound to the T877A AR variant. Additionally, we demonstrated that R-bicalutamide stimulates transcriptional activation in AR harboring the M895T point mutation. As a whole, these studies provide critical new insight for receptor-based drug design of nonsteroidal AR agonists and antagonists.
About this StructureAbout this Structure
2AXA is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.
ReferenceReference
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor., Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT, J Biol Chem. 2005 Nov 11;280(45):37747-54. Epub 2005 Aug 29. PMID:16129672 Page seeded by OCA on Sat May 3 19:35:10 2008